An exceptional safety profile has been shown in a large number of cell therapy clinical trials
that use mesenchymal stromal cells (MSCs). However, reliable potency assays are still …

Heart transplantation is advocated in selected patients with advanced heart failure in the
absence of contraindications. Principal challenges in heart transplantation centre around an …

The use of routine monitoring of donor-derived cell-free DNA (dd-cfDNA) after kidney
transplant may allow clinicians to identify subclinical allograft injury and intervene prior to …

The premier single-volume reference in the field of anesthesia, Clinical Anesthesia is now in
its Sixth Edition, with thoroughly updated coverage, a new full-color design, and a revamped …

Background The relationship between the donor-derived cell-free DNA fraction (dd-cfDNA
[%]) in plasma in kidney transplant recipients at time of indication biopsy and gene …

There is a need to improve personalized immunosuppression in organ transplantation to
reduce premature graft loss. Biomarkers are needed to better detect rejection, asymptomatic …

Background: Endomyocardial biopsy (EMB) is the gold standard method for surveillance of
acute cardiac allograft rejection (ACAR) despite its invasive nature. Cardiovascular …

Multisystem inflammatory syndrome in children (MIS-C) is a rare but life-threatening
hyperinflammatory condition induced by infection with severe acute respiratory syndrome …

This review describes the development of the Molecular Microscope Diagnostic System
(MMDx) for heart transplant endomyocardial biopsies (EMBs). MMDx-Heart uses …

Donor-derived cell-free DNA (dd-cfDNA) has been evaluated as a rejection marker in organ
transplantation. This study sought to assess the utility of dd-cfDNA to diagnose graft injury in …